

Preauthorization Rates by Prescriber Specialty

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Prescriber Specialty	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ADOLESCENT MEDICINE	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
ADVANCED PRACTICE NURSE	225	73.3%	82	26.7%	0	0.0%	0	0.0%	307	0	0	0
ALLERGY & IMMUNOLOGY	76	83.5%	15	16.5%	0	0.0%	0	0.0%	91	0	0	0
ANESTHESIOLOGY	6	46.2%	7	53.8%	0	0.0%	0	0.0%	13	0	0	0
CARDIAC ELECTROPHYSIOLOGY	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
CARDIOLOGY	69	77.5%	20	22.5%	0	0.0%	0	0.0%	89	0	0	0
CARDIOLOGY, INTERVENTIONAL	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
CARDIOLOGY, PEDIATRIC	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
CERTIFIED NURSE MIDWIFE	5	55.6%	4	44.4%	0	0.0%	0	0.0%	9	0	0	0
CERTIFIED REGISTERED NURSE ANESTHETIST	0	0.0%	5	100.0%	0	0.0%	0	0.0%	5	0	0	0
DERMATOLOGY	397	82.0%	87	18.0%	0	0.0%	0	0.0%	484	0	0	0
EMERGENCY MEDICINE	123	91.8%	11	8.2%	0	0.0%	0	0.0%	134	0	0	0
EMERGENCY MEDICINE, PEDIATRIC	6	85.7%	1	14.3%	0	0.0%	0	0.0%	7	0	0	0
ENDOCRINOLOGY, DIABETES & METABOLISM	192	85.7%	32	14.3%	0	0.0%	0	0.0%	224	0	0	0
ENDOCRINOLOGY, PEDIATRIC	85	95.5%	4	4.5%	0	0.0%	0	0.0%	89	0	0	0
ENDOCRINOLOGY, REPRODUCTIVE	13	72.2%	5	27.8%	0	0.0%	0	0.0%	18	0	0	0
FAMILY PRACTICE	959	71.4%	384	28.6%	0	0.0%	0	0.0%	1,343	0	0	0
GASTROENTEROLOGY	100	75.2%	33	24.8%	0	0.0%	0	0.0%	133	0	0	0
GASTROENTEROLOGY, PEDIATRIC	12	70.6%	5	29.4%	0	0.0%	0	0.0%	17	0	0	0
GENERAL PRACTICE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Prescriber Specialty

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Prescriber Specialty	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
GENETICS	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
GERIATRIC MEDICINE	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
HEMATOLOGY	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
HEMATOLOGY & ONCOLOGY	79	89.8%	9	10.2%	0	0.0%	0	0.0%	88	0	0	0
HEMATOLOGY & ONCOLOGY, PEDIATRIC	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
HOSPITALIST	34	100.0%	0	0.0%	0	0.0%	0	0.0%	34	0	0	0
INFECTIOUS DISEASES	34	89.5%	4	10.5%	0	0.0%	0	0.0%	38	0	0	0
INTERNAL MEDICINE	699	79.7%	178	20.3%	0	0.0%	0	0.0%	877	0	0	0
LEGAL MEDICINE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
MATERNAL & FETAL MEDICINE	40	100.0%	0	0.0%	0	0.0%	0	0.0%	40	0	0	0
NEPHROLOGY/RENAL MEDICINE	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
NEPHROLOGY/RENAL MEDICINE, PEDIATRIC	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
NEURODEVELOPMENTAL DISABILITIES, PEDIATRIC	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
NEUROLOGY	279	67.7%	133	32.3%	0	0.0%	0	0.0%	412	0	0	0
NEUROLOGY, PEDIATRIC	3	50.0%	3	50.0%	0	0.0%	0	0.0%	6	0	0	0
NEUROPHYSIOLOGY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NURSE PRACTITIONER	362	55.1%	295	44.9%	0	0.0%	0	0.0%	657	0	0	0
OBSTETRICS & GYNECOLOGY	200	74.9%	67	25.1%	0	0.0%	0	0.0%	267	0	0	0
ONCOLOGY, GYNECOLOGIC	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ONCOLOGY, MEDICAL	16	88.9%	2	11.1%	0	0.0%	0	0.0%	18	0	0	0
OPHTHALMOLOGY	47	74.6%	16	25.4%	0	0.0%	0	0.0%	63	0	0	0
OPTOMETRIST	33	66.0%	17	34.0%	0	0.0%	0	0.0%	50	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Prescriber Specialty

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Prescriber Specialty	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
OSTEOPATHIC MANIPULATIVE MEDICINE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
OTOLARYNGOLOGY	18	85.7%	3	14.3%	0	0.0%	0	0.0%	21	0	0	0
PAIN MEDICINE	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
PEDIATRICS	219	82.0%	48	18.0%	0	0.0%	0	0.0%	267	0	0	0
PHYSICAL MEDICINE & REHABILITATION	3	37.5%	5	62.5%	0	0.0%	0	0.0%	8	0	0	0
PHYSICIAN ASSISTANT	789	75.6%	255	24.4%	0	0.0%	0	0.0%	1,044	0	0	0
PODIATRIST	0	0.0%	7	100.0%	0	0.0%	0	0.0%	7	0	0	0
PSYCHIATRY	258	79.6%	66	20.4%	0	0.0%	0	0.0%	324	0	0	0
PSYCHIATRY, CHILD & ADOLESCENT	13	81.2%	3	18.8%	0	0.0%	0	0.0%	16	0	0	0
PULMONARY DISEASE	14	87.5%	2	12.5%	0	0.0%	0	0.0%	16	0	0	0
PULMONOLOGY, PEDIATRIC	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
RHEUMATOLOGY	79	91.9%	7	8.1%	0	0.0%	0	0.0%	86	0	0	0
SLEEP MEDICINE	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
SURGERY, GENERAL	7	70.0%	3	30.0%	0	0.0%	0	0.0%	10	0	0	0
SURGERY, NEUROLOGICAL	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
SURGERY, ONCOLOGY	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
SURGERY, ORTHOPEDIC	9	81.8%	2	18.2%	0	0.0%	0	0.0%	11	0	0	0
SURGERY, PLASTIC	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
SURGERY, VASCULAR	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
UROLOGY	6	33.3%	12	66.7%	0	0.0%	0	0.0%	18	0	0	0
	2,457	89.1%	300	10.9%	0	0.0%	0	0.0%	2,757	0	0	0
Overall - Summary	8,040	78.9%	2,155	21.1%	0	0.0%	0	0.0%	10,195	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
2ND GEN. ANAEROBIC ANTIPROTOZOAL-ANTIBACTERIAL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATION	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACE INHIBITOR/THIAZIDE & THIAZIDE-LIKE DIURETIC	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
ACNE AGENTS, TOPICAL	7	29.2%	17	70.8%	0	0.0%	0	0.0%	24	0	0	0
ADRENERGIC VASOPRESSOR AGENTS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	252	70.0%	108	30.0%	0	0.0%	0	0.0%	360	0	0	0
ADRENOCORTICOTROPHIC HORMONES	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
AGENTS TO TREAT MULTIPLE SCLEROSIS	45	67.2%	22	32.8%	0	0.0%	0	0.0%	67	0	0	0
ALLERGENIC EXTRACTS, THERAPEUTICS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ALPHA/BETA-ADRENERGIC BLOCKING AGENTS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
ALZHEIMER'S THERAPY, NMDA RECEPTOR ANTAGONISTS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANALGESIC, NON-SALICYLATE, BARBITURATE, & XANTHINE CMB	10	66.7%	5	33.3%	0	0.0%	0	0.0%	15	0	0	0
ANALGESICS, NARCOTIC AGONIST AND NSAID COMBINATION	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANALGESICS, NARCOTICS	61	70.9%	25	29.1%	0	0.0%	0	0.0%	86	0	0	0
ANAPHYLAXIS THERAPY AGENTS	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
ANDROGENIC AGENTS	11	50.0%	11	50.0%	0	0.0%	0	0.0%	22	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ANGIOTENSIN RECEPTOR ANTAG./THIAZIDE DIURETIC COMB	5	62.5%	3	37.5%	0	0.0%	0	0.0%	8	0	0	0
ANGIOTENSIN RECEPTOR ANTGNST & CALC.CHANNEL BLOCKR	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANOREXIC AGENTS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTI-ANXIETY - BENZODIAZEPINES	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
ANTI-ANXIETY DRUGS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTI-ARTHRITIC, FOLATE ANTAGONIST AGENTS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTI-FLAM. INTERLEUKIN-1 RECEPTOR ANTAGONIST	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	263	92.9%	20	7.1%	0	0.0%	0	0.0%	283	0	0	0
ANTI-INFLAMMATORY, INTERLEUKIN-1 BETA BLOCKERS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ANTI-MANIA DRUGS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ANTI-MYCOBACTERIUM AGENTS	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
ANTI-NARCOLEPSY & ANTI-CATAPLEXY,SEDATIVE-TYPE AGT	16	76.2%	5	23.8%	0	0.0%	0	0.0%	21	0	0	0
ANTI-OBESITY - OPIOID ANTAG/NOREPI & DA REUP INHIB	3	42.9%	4	57.1%	0	0.0%	0	0.0%	7	0	0	0
ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST	2	8.3%	22	91.7%	0	0.0%	0	0.0%	24	0	0	0
ANTI-PSYCHOTICS,PHENOTHIAZINES	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANTI-ULCER PREPARATIONS	17	68.0%	8	32.0%	0	0.0%	0	0.0%	25	0	0	0
ANTIANDROGENIC AGENTS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ANTIANGINAL & ANTI-ISCHEMIC AGENTS,NON-HEMODYNAMIC	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ANTIANGINAL, HEART RATE REDUCING, I(F) INHIBITOR	8	66.7%	4	33.3%	0	0.0%	0	0.0%	12	0	0	0
ANTIARRHYTHMICS	11	91.7%	1	8.3%	0	0.0%	0	0.0%	12	0	0	0
ANTICHOLINERGIC, ORALLY INHALED SHORT ACTING	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	4	44.4%	5	55.6%	0	0.0%	0	0.0%	9	0	0	0
ANTICHOLINERGICS,QUATERNARY AMMONIUM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ANTICOAGULANTS,COUMARIN TYPE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ANTICONVULSANT - BENZODIAZEPINE TYPE	7	50.0%	7	50.0%	0	0.0%	0	0.0%	14	0	0	0
ANTICONVULSANT - CANNABINOID TYPE	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
ANTICONVULSANTS	94	75.8%	30	24.2%	0	0.0%	0	0.0%	124	0	0	0
ANTIDIARRHEALS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIEMETIC/ANTIVERTIGO AGENTS	26	86.7%	4	13.3%	0	0.0%	0	0.0%	30	0	0	0
ANTIFIBRINOLYTIC AGENTS	18	52.9%	16	47.1%	0	0.0%	0	0.0%	34	0	0	0
ANTIFIBROTIC THERAPY - PYRIDONE ANALOGS	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
ANTIFUNGAL AGENTS	49	89.1%	6	10.9%	0	0.0%	0	0.0%	55	0	0	0
ANTIHISTAMINES - 1ST GENERATION	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR.AGONIST)	222	47.8%	242	52.2%	0	0.0%	0	0.0%	464	0	0	0
ANTIHYPERGLYCEMIC-SOD/GLUCOCOTRANSPORT2(SGLT2)INHIB	31	62.0%	19	38.0%	0	0.0%	0	0.0%	50	0	0	0
ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION	0	0.0%	64	100.0%	0	0.0%	0	0.0%	64	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ANTIHYPERGLYCEMIC, DPP-4 INHIBITORS	18	46.2%	21	53.8%	0	0.0%	0	0.0%	39	0	0	0
ANTIHYPERGLYCEMIC, INSULIN-RELEASE STIMULANT TYPE	19	95.0%	1	5.0%	0	0.0%	0	0.0%	20	0	0	0
ANTIHYPERGLYCEMIC,BIGUANIDE TYPE(NON-SULFONYLUREA)	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
ANTIHYPERGLYCEMIC-SGLT2 INHIBITOR & BIGUANIDE COMB	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
ANTIHYPERLIPIDEMIC - ATP CITRATE LYASE INHIBITOR	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
ANTIHYPERLIPIDEMIC - PCSK9 INHIBITORS	111	87.4%	16	12.6%	0	0.0%	0	0.0%	127	0	0	0
ANTIHYPERLIPIDEMIC-ACLY AND CHOLES ABSORP INHIB	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIHYPERTENSIVES, ACE INHIBITORS	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
ANTIHYPERTENSIVES, ANGIOTENSIN RECEPTOR ANTAGONIST	15	60.0%	10	40.0%	0	0.0%	0	0.0%	25	0	0	0
ANTIHYPERTENSIVES, SYMPATHOLYTIC	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
ANTIHYPERTENSIVES, VASODILATORS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIMALARIAL DRUGS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIMETABOLITES	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTIMIGRAINE PREPARATIONS	490	70.3%	207	29.7%	0	0.0%	0	0.0%	697	0	0	0
ANTINEOPLASTIC - BRAF KINASE INHIBITORS	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
ANTINEOPLASTIC - MEK1 AND MEK2	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
KINASE INHIBITORS												
ANTINEOPLASTIC - MTOR KINASE INHIBITORS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
ANTINEOPLASTIC IMMUNOMODULATOR AGENTS	18	100.0%	0	0.0%	0	0.0%	0	0.0%	18	0	0	0
ANTINEOPLASTIC LHRH(GNRH) AGONIST,PITUITARY SUPPR.	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	90	88.2%	12	11.8%	0	0.0%	0	0.0%	102	0	0	0
ANTINEOPLASTIC-B CELL LYMPHOMA-2(BCL-2) INHIBITORS	12	100.0%	0	0.0%	0	0.0%	0	0.0%	12	0	0	0
ANTINEOPLASTIC-ISOCITRATE DEHYDROGENASE INHIBITORS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTINFLAMMATORY, SEL.COSTIM.MOD.,T-CELL INHIBITOR	26	96.3%	1	3.7%	0	0.0%	0	0.0%	27	0	0	0
ANTIPARASITICS	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ANTIPARKINSONISM DRUGS,ANTICHOLINERGIC	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ANTIPARKINSONISM DRUGS,OTHER	20	90.9%	2	9.1%	0	0.0%	0	0.0%	22	0	0	0
ANTIPSORIATIC AGENTS,SYSTEMIC	44	60.3%	29	39.7%	0	0.0%	0	0.0%	73	0	0	0
ANTIPSORIATICS AGENTS	9	64.3%	5	35.7%	0	0.0%	0	0.0%	14	0	0	0
ANTIPSYCHOTIC-ATYPICAL,D3/D2 PARTIAL AG-5HT MIXED	36	78.3%	10	21.7%	0	0.0%	0	0.0%	46	0	0	0
ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	15	78.9%	4	21.1%	0	0.0%	0	0.0%	19	0	0	0
ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& SEROTONIN ANTAG	82	77.4%	24	22.6%	0	0.0%	0	0.0%	106	0	0	0
ANTIRETROVIRAL-NUCLEOSIDE,NUCLEOTIDE,PROTEASE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
INH.												
ANTITUBERCULAR ANTIBIOTICS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ANTIVIRALS, GENERAL	39	70.9%	16	29.1%	0	0.0%	0	0.0%	55	0	0	0
ANTIVIRALS, HIV-SPEC, NUCLEOSIDE-NUCLEOTIDE ANALOG	35	87.5%	5	12.5%	0	0.0%	0	0.0%	40	0	0	0
ARV CMB-NRTI,N(T)RTI, INTEGRASE INHIBITOR	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ARV COMB-NRTIS & INTEGRASE INHIBITOR	25	92.6%	2	7.4%	0	0.0%	0	0.0%	27	0	0	0
BELLADONNA ALKALOIDS	6	54.5%	5	45.5%	0	0.0%	0	0.0%	11	0	0	0
BENIGN PROSTATIC HYPERTROPHY/MICTURITION AGENTS	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	25	80.6%	6	19.4%	0	0.0%	0	0.0%	31	0	0	0
BETA-ADRENERGIC AGENTS, ORALLY INHALED, LONG ACTING	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BETA-ADRENERGIC AND ANTICHOLINERGIC COMBINATIONS	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
BETA-ADRENERGIC AND GLUCOCORTICOID COMBINATIONS	103	74.1%	36	25.9%	0	0.0%	0	0.0%	139	0	0	0
BETA-ADRENERGIC BLOCKING AGENTS	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
BETA-ADRENERGIC-ANTICHOLINERGIC-GLUCOCORT, INHALED	5	15.6%	27	84.4%	0	0.0%	0	0.0%	32	0	0	0
BILE SALT SEQUESTRANTS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
BLOOD SUGAR DIAGNOSTICS	198	99.5%	1	0.5%	0	0.0%	0	0.0%	199	0	0	0
BLOOD TESTING PREPARATIONS, IN-VITRO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
BONE FORMATION STIM. AGENTS -	42	84.0%	8	16.0%	0	0.0%	0	0.0%	50	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
PARATHYROID HORMONE												
BONE FORMATION STIMULATING AGTS - PTH REL PEPTIDES	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
BONE RESORPTION INHIBITORS	16	94.1%	1	5.9%	0	0.0%	0	0.0%	17	0	0	0
BULK CHEMICALS	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
C1 ESTERASE INHIBITORS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CALCITONIN GENE-RELATED PEPTIDE (CGRP) INHIBITORS	9	69.2%	4	30.8%	0	0.0%	0	0.0%	13	0	0	0
CALCIUM CHANNEL BLOCKING AGENTS	5	71.4%	2	28.6%	0	0.0%	0	0.0%	7	0	0	0
CEPHALOSPORINS - 1ST GENERATION	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CEPHALOSPORINS - 3RD GENERATION	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CHEMOTHERAPEUTICS, ANTIBACTERIAL, MISC.	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
CHEMOTHERAPY RESCUE/ANTIDOTE AGENTS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CHOLINESTERASE INHIBITORS	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
COLCHICINE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
CONTRACEPTIVES, INJECTABLE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CONTRACEPTIVES, ORAL	33	61.1%	21	38.9%	0	0.0%	0	0.0%	54	0	0	0
CYSTIC FIBROSIS-CFTR POTENTIATOR & CORRECTOR COMB.	10	90.9%	1	9.1%	0	0.0%	0	0.0%	11	0	0	0
DECARBOXYLASE INHIBITORS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
DIABETIC SUPPLIES	396	99.0%	4	1.0%	0	0.0%	0	0.0%	400	0	0	0
DIAPHRAGMS/CERVICAL CAP	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
DIRECT FACTOR XA INHIBITORS	372	91.6%	34	8.4%	0	0.0%	0	0.0%	406	0	0	0
DRUG TX-CHRONIC INFLAM. COLON DX,5-AMINOSALICYLAT	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
DRUGS TO TREAT IMPOTENCY	4	36.4%	7	63.6%	0	0.0%	0	0.0%	11	0	0	0
DURABLE MEDICAL EQUIPMENT,MISC(GROUP 1)	171	100.0%	0	0.0%	0	0.0%	0	0.0%	171	0	0	0
EAR PREPARATIONS ANTI-INFLAMMATORY	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ELECTROLYTE DEPLETERS	14	70.0%	6	30.0%	0	0.0%	0	0.0%	20	0	0	0
ESTROGENIC AGENTS	59	73.8%	21	26.2%	0	0.0%	0	0.0%	80	0	0	0
EYE ANTIBIOTIC-CORTICOID COMBINATIONS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
EYE ANTIHISTAMINES	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
EYE ANTIINFLAMMATORY AGENTS	19	79.2%	5	20.8%	0	0.0%	0	0.0%	24	0	0	0
EYE ANTIVIRALS	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
FARNESOID X RECEPTOR (FXR) AGONIST, BILE AC ANALOG	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FAT ABSORPTION DECREASING AGENTS	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
FERTILITY STIMULATING PREPARATIONS,NON-FSH	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
FIBROMYALGIA AGENTS,SEROTONIN-NOREPINEPH RU INHIB	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
FOLIC ACID PREPARATIONS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
GASTRIC ENZYMES	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
GENERAL INHALATION AGENTS	20	100.0%	0	0.0%	0	0.0%	0	0.0%	20	0	0	0
GENETIC D/O TX-EXON INCLUSION ANTISENSE OLIGONUCLE	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
GLUCOCORTICOIDS	15	100.0%	0	0.0%	0	0.0%	0	0.0%	15	0	0	0
GLUCOCORTICOIDS, ORALLY INHALED	44	64.7%	24	35.3%	0	0.0%	0	0.0%	68	0	0	0
GROWTH HORMONE RECEPTOR ANTAGONISTS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
GROWTH HORMONES	138	90.2%	15	9.8%	0	0.0%	0	0.0%	153	0	0	0
HEMORRHOIDAL PREP, ANTI-INFAM STEROID/LOCAL ANESTH	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
HEP C VIRUS - NS5A & NS5B POLYMERASE INHIB. COMBO.	36	97.3%	1	2.7%	0	0.0%	0	0.0%	37	0	0	0
HEPARIN AND RELATED PREPARATIONS	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
HEPATITIS B TREATMENT AGENTS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
HSDD AGENTS-MIXED SEROTONIN AGONIST/ANTAGONISTS	0	0.0%	7	100.0%	0	0.0%	0	0.0%	7	0	0	0
HUMAN CHORIONIC GONADOTROPIN (HCG)	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HYPERGLYCEMICS	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
HYPERURICEMIA TX - PURINE INHIBITORS	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
HYPNOTICS, MELATONIN MT1/MT2 RECEPTOR AGONISTS	24	92.3%	2	7.7%	0	0.0%	0	0.0%	26	0	0	0
IBS AGENTS,MIXED OPIOID RECEPTOR AGONISTS/ANTAGONISTS	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
IL-23 RECEPTOR ANTAGONIST, MONOCLONAL ANTIBODY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
IMMUNOMODULATOR,B-LYMPHOCYTE STIM(BLYS)-SPEC INHIB	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
IMMUNOSUPPRESSIVES	40	90.9%	4	9.1%	0	0.0%	0	0.0%	44	0	0	0
INSULINS	1,249	91.4%	118	8.6%	0	0.0%	0	0.0%	1,367	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
INTERLEUKIN-13 (IL-13) INHIBITORS, MAB	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
INTERLEUKIN-4(IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	190	80.2%	47	19.8%	0	0.0%	0	0.0%	237	0	0	0
INTERLEUKIN-5(IL-5) RECEPTOR ALPHA ANTAGONIST, MAB	35	83.3%	7	16.7%	0	0.0%	0	0.0%	42	0	0	0
INTERLEUKIN-6 (IL-6) RECEPTOR INHIBITORS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
INTESTINAL MOTILITY STIMULANTS	13	52.0%	12	48.0%	0	0.0%	0	0.0%	25	0	0	0
IRON REPLACEMENT	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
IRRITABLE BOWEL AGENTS,GUANYLATE CYLASE-C AGONIST	148	73.3%	54	26.7%	0	0.0%	0	0.0%	202	0	0	0
IRRITABLE BOWEL SYND. AGENT,5HT-4 PARTIAL AGONIST	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
JANUS KINASE (JAK) INHIBITORS	29	67.4%	14	32.6%	0	0.0%	0	0.0%	43	0	0	0
KERATOLYTICS	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
KIDNEY STONE AGENTS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
LAXATIVES AND CATHARTICS	237	96.3%	9	3.7%	0	0.0%	0	0.0%	246	0	0	0
LEUKOCYTE (WBC) STIMULANTS	7	87.5%	1	12.5%	0	0.0%	0	0.0%	8	0	0	0
LEUKOTRIENE RECEPTOR ANTAGONISTS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
LHRH (GNRH) ANTAGONIST,ESTROGEN AND PROGESTIN COMB	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
LHRH(GNRH) ANTAGONIST,PITUITARY SUPPRESSANT AGENTS	7	77.8%	2	22.2%	0	0.0%	0	0.0%	9	0	0	0
LINCOSAMIDES	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LIPOTROPICS	14	66.7%	7	33.3%	0	0.0%	0	0.0%	21	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
LOCAL ANESTHETICS	2	33.3%	4	66.7%	0	0.0%	0	0.0%	6	0	0	0
LOOP DIURETICS	7	87.5%	1	12.5%	0	0.0%	0	0.0%	8	0	0	0
MACROLIDES	22	71.0%	9	29.0%	0	0.0%	0	0.0%	31	0	0	0
MAST CELL STABILIZERS	6	66.7%	3	33.3%	0	0.0%	0	0.0%	9	0	0	0
MENOPAUSAL SYMPTOMS SUPPRESSANT - SSRIS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
METABOLIC DISEASE ENZYME REPLACE, HYPOPHOSPHATASIA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
METALLIC POISON,AGENTS TO TREAT	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
MIOTICS/OTHER INTRAOC. PRESSURE REDUCERS	49	73.1%	18	26.9%	0	0.0%	0	0.0%	67	0	0	0
MONOCLONAL ANTIBODIES TO IMMUNOGLOBULIN E(IGE)	17	85.0%	3	15.0%	0	0.0%	0	0.0%	20	0	0	0
MONOCLONAL ANTIBODY - INTERLEUKIN-5 ANTAGONISTS	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
MONOCLONAL ANTIBODY-HUMAN INTERLEUKIN 12/23 INHIB	69	92.0%	6	8.0%	0	0.0%	0	0.0%	75	0	0	0
MOVEMENT DISORDERS(DRUG THERAPY)	2	33.3%	4	66.7%	0	0.0%	0	0.0%	6	0	0	0
MYDRIATICS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
NARC.& NON-SAL.ANALGESIC,BARBITURATE &XANTHINE CMB	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
NARCOLEPSY AND SLEEP DISORDER THERAPY AGENTS	21	91.3%	2	8.7%	0	0.0%	0	0.0%	23	0	0	0
NARCOLEPSY TX-H3-RECEPT.ANTAGONIST/INVERSE AGONIST	12	92.3%	1	7.7%	0	0.0%	0	0.0%	13	0	0	0
NARCOTIC ANALGESIC & NON-SALICYLATE ANALGESIC COMB	0	0.0%	5	100.0%	0	0.0%	0	0.0%	5	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
NARCOTIC ANTAGONISTS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NARCOTIC ANTAGONISTS, PERIPHERALLY-ACTING	5	50.0%	5	50.0%	0	0.0%	0	0.0%	10	0	0	0
NARCOTIC WITHDRAWAL THERAPY AGENTS	27	90.0%	3	10.0%	0	0.0%	0	0.0%	30	0	0	0
NASAL ANTI-INFLAMMATORY STEROIDS	0	0.0%	5	100.0%	0	0.0%	0	0.0%	5	0	0	0
NASAL ANTIHISTAMINE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NASAL ANTIHISTAMINE & ANTI-INFLAM. STEROID COMB.	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NATRIURETIC PEPTIDES	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NDMA RECEPTOR ANTAGONIST AND NDRI COMB	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NEEDLES/NEEDLELESS DEVICES	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
NICOTINIC RECEPT.PARTIAL AGONIST, ALPHA4BETA2 SPEC	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIB (NDRIS)	25	80.6%	6	19.4%	0	0.0%	0	0.0%	31	0	0	0
NOSE PREPARATIONS, MISCELLANEOUS (RX)	47	85.5%	8	14.5%	0	0.0%	0	0.0%	55	0	0	0
NSAID & HISTAMINE H2 RECEPTOR ANTAGONIST COMB.	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NSAIDS, CYCLOOXYGENASE 2 INHIBITOR - TYPE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NSAIDS, CYCLOOXYGENASE INHIBITOR-TYPE	4	36.4%	7	63.6%	0	0.0%	0	0.0%	11	0	0	0
OPHTHALMIC ANTI-INFLAMMATORY IMMUNOMODULATOR-TYPE	46	71.9%	18	28.1%	0	0.0%	0	0.0%	64	0	0	0
OPHTHALMIC ANTIBIOTICS	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
OPHTHALMIC ANTIFUNGAL AGENTS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
OPIOID WITHDRAWAL THER, ALPHA-2 ADRENERGIC AGONIST	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
OVERACTIVE BLADDER AGENTS, BETA-3 ADRENERGIC RECEPTOR	6	21.4%	22	78.6%	0	0.0%	0	0.0%	28	0	0	0
OXAZOLIDINONES	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
PANCREATIC ENZYMES	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
PARASYMPATHETIC AGENTS	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
PENICILLINS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
PHOSPHODIESTERASE-4 (PDE4) INHIBITORS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
PKU TREATMENT AGENTS - PHENYLALANINE AMMONIA LYASE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
PKU TX AGENT-COFACTOR OF PHENYLALANINE HYDROXYLASE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PLASMA KALLIKREIN INHIBITORS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
POLYCYSTIC KIDNEY DISEASE AGENT, AVP RECEPTOR ANTAGONIST	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
POSTHERPETIC NEURALGIA AGENTS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
POTASSIUM REPLACEMENT	9	75.0%	3	25.0%	0	0.0%	0	0.0%	12	0	0	0
POTASSIUM SPARING DIURETICS	17	85.0%	3	15.0%	0	0.0%	0	0.0%	20	0	0	0
PREGNANCY FACILITATING/MAINTAINING AGENT, HORMONAL	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
PROGESTATIONAL AGENTS	37	56.9%	28	43.1%	0	0.0%	0	0.0%	65	0	0	0
PROTEIN STABILIZERS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PROTON-PUMP INHIBITORS	7	41.2%	10	58.8%	0	0.0%	0	0.0%	17	0	0	0
PSEUDOBULBAR AFFECT (PBA) AGENTS,	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
NMDA ANTAGONISTS												
PULM ANTI-HTN,SOLUBLE GUANYLATE CYCLASE STIMULATOR	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
PULM.ANTI-HTN,SEL.C-GMP PHOSPHODIESTERASE T5 INHIB	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
PULMONARY ANTI-HTN, ENDOTHELIN RECEPTOR ANTAGONIST	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
PULMONARY ANTIHYPERTENSIVES, PROSTACYCLIN-TYPE	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
PULMONARY FIBROSIS - SYSTEMIC ENZYME INHIBITORS	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
QUINOLONES	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
RECTAL/LOWER BOWEL PREP.,GLUCOCORT. (NON-HEMORR)	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
RENIN INHIBITOR, DIRECT	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
RHO KINASE INHIBITOR	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
RIFAMYCINS AND RELATED DERIVATIVE ANTIBIOTICS	56	40.9%	81	59.1%	0	0.0%	0	0.0%	137	0	0	0
ROSACEA AGENTS, TOPICAL	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
SBS - GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOGS	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
SEDATIVE-HYPNOTICS - BENZODIAZEPINES	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
SEDATIVE-HYPNOTICS,NON-BARBITURATE	51	69.9%	22	30.1%	0	0.0%	0	0.0%	73	0	0	0
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	32	78.0%	9	22.0%	0	0.0%	0	0.0%	41	0	0	0
SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	60	80.0%	15	20.0%	0	0.0%	0	0.0%	75	0	0	0
SKELETAL MUSCLE RELAXANTS	6	75.0%	2	25.0%	0	0.0%	0	0.0%	8	0	0	0
SMOKING DETERRENT-NICOTINIC RECEPT.PARTIAL AGONIST	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
SOMATOSTATIC AGENTS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATOR	6	66.7%	3	33.3%	0	0.0%	0	0.0%	9	0	0	0
SPLEEN TYROSINE KINASE INHIBITORS	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
SSRI & 5HT1A PARTIAL AGONIST ANTIDEPRESSANT	54	88.5%	7	11.5%	0	0.0%	0	0.0%	61	0	0	0
SSRI & SEROTONIN RECEPTOR MODULATOR ANTIDEPRESSANT	48	69.6%	21	30.4%	0	0.0%	0	0.0%	69	0	0	0
SYRINGES AND ACCESSORIES	12	100.0%	0	0.0%	0	0.0%	0	0.0%	12	0	0	0
TETRACYCLINES	8	66.7%	4	33.3%	0	0.0%	0	0.0%	12	0	0	0
THIAZIDE AND RELATED DIURETICS	6	85.7%	1	14.3%	0	0.0%	0	0.0%	7	0	0	0
THROMBIN INHIBITORS,SELECTIVE,DIRECT, & REVERSIBLE	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
THROMBOPOIETIN RECEPTOR AGONISTS	12	92.3%	1	7.7%	0	0.0%	0	0.0%	13	0	0	0
THYMIC STROMAL LYMPHOPOIETIN (TSLP) INHIBITORS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
THYROID HORMONES	28	32.9%	57	67.1%	0	0.0%	0	0.0%	85	0	0	0
TOP. ANTI-INFLAM.,PHOSPHODIESTERASE-4 (PDE4) INHIB	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
TOPICAL ANTI-INFLAMMATORY STEROID-LOCAL ANESTHETIC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
TOPICAL ANTI-INFLAMMATORY STEROIDAL	5	45.5%	6	54.5%	0	0.0%	0	0.0%	11	0	0	0
TOPICAL ANTI-INFLAMMATORY, NSAIDS	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
TOPICAL ANTIANDROGENIC AGENTS	2	22.2%	7	77.8%	0	0.0%	0	0.0%	9	0	0	0
TOPICAL ANTIBIOTICS	0	0.0%	4	100.0%	0	0.0%	0	0.0%	4	0	0	0
TOPICAL ANTICHOLINERGIC HYPERHIDROSIS TX AGENTS	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
TOPICAL ANTIFUNGALS	7	38.9%	11	61.1%	0	0.0%	0	0.0%	18	0	0	0
TOPICAL ANTINEOPLASTIC & PREMALIGNANT LESION AGENTS	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
TOPICAL ANTIPARASITICS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TOPICAL ANTIVIRALS	1	20.0%	4	80.0%	0	0.0%	0	0.0%	5	0	0	0
TOPICAL IMMUNOSUPPRESSIVE AGENTS	12	66.7%	6	33.3%	0	0.0%	0	0.0%	18	0	0	0
TOPICAL JANUS KINASE (JAK) INHIBITORS	3	37.5%	5	62.5%	0	0.0%	0	0.0%	8	0	0	0
TOPICAL LOCAL ANESTHETICS	1	20.0%	4	80.0%	0	0.0%	0	0.0%	5	0	0	0
TOPICAL SULFONAMIDES	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TOPICAL VIT D ANALOG/ANTIINFLAMMATORY, STEROIDAL	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TRICYCLIC ANTIDEPRESSANTS & REL. NON-SEL. RU-INHIB	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TX FOR ADHD - SELECTIVE ALPHA-2A RECEPTOR AGONIST	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	54	64.3%	30	35.7%	0	0.0%	0	0.0%	84	0	0	0
TX FOR ATTENTION DEFICIT-HYPERACT. (ADHD), NRI-TYPE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Therapeutic Class

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Therapeutic Class	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
URINARY TRACT ANTISPASMODIC, M(3) SELECTIVE ANTAG.	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
URINARY TRACT ANTISPASMODIC/ANTIINCONTINENCE AGENT	6	54.5%	5	45.5%	0	0.0%	0	0.0%	11	0	0	0
VAGINAL ANTIFUNGALS	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
VAGINAL ANTISEPTICS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
VAGINAL ESTROGEN FOR SEXUAL DYSFUNCTION	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
VAGINAL ESTROGEN PREPARATIONS	133	87.5%	19	12.5%	0	0.0%	0	0.0%	152	0	0	0
VITAMIN A DERIVATIVES	586	97.7%	14	2.3%	0	0.0%	0	0.0%	600	0	0	0
VITAMIN B12 PREPARATIONS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
VITAMIN D PREPARATIONS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
Overall - Summary	8,040	78.9%	2,155	21.1%	0	0.0%	0	0.0%	10,195	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ABILIFY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ABIRATERONE ACETATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACCU-CHEK	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACCU-CHEK AVIVA PLUS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACCU-CHEK GUIDE TEST STRIP	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ACCU-CHEK SOFTCLIX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACTEMRA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACTHAR	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACTONEL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ACYCLOVIR	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
ADAPALENE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ADAPALENE-BENZOYL PEROXIDE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
ADBRY	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
ADDERALL	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
ADDERALL XR	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
ADDYI	0	0.0%	7	100.0%	0	0.0%	0	0.0%	7	0	0	0
ADEMPAS	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
ADVAIR DISKUS	6	42.9%	8	57.1%	0	0.0%	0	0.0%	14	0	0	0
ADVAIR HFA	64	80.0%	16	20.0%	0	0.0%	0	0.0%	80	0	0	0
ADZENYS XR-ODT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
AIMOVIQ AUTOINJECTOR	55	73.3%	20	26.7%	0	0.0%	0	0.0%	75	0	0	0
AJOVY AUTOINJECTOR	105	97.2%	3	2.8%	0	0.0%	0	0.0%	108	0	0	0
AJOVY SYRINGE	11	100.0%	0	0.0%	0	0.0%	0	0.0%	11	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
AKLIEF	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
ALBUTEROL SULFATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ALBUTEROL SULFATE HFA	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ALECENSA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ALISKIREN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ALMOTRIPTAN MALATE	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
ALOGLIPTIN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ALPHAGAN P	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
ALUNBRIG	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ALVESCO	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
AMIODARONE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
AMITIZA	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
AMITRIPTYLINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AMLODIPINE BESYLATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
AMLODIPINE BESYLATE-BENAZEPRIL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AMLODIPINE-OLMESARTAN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
AMOXICILLIN-CLAVULANATE POTASS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
AMPHETAMINE SULFATE	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
AMZEEQ	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ANDRODERM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ANORO ELLIPTA	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
APIDRA	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
APLENZIN	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
APREPITANT	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
APTIOM	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
ARCALYST	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ARIPIRAZOLE	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
ARMOUR THYROID	7	58.3%	5	41.7%	0	0.0%	0	0.0%	12	0	0	0
ASENAPINE MALEATE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
ASMANEX	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
ASMANEX HFA	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
ATACAND	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ATROPINE SULFATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ATROVENT HFA	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
AUBAGIO	9	52.9%	8	47.1%	0	0.0%	0	0.0%	17	0	0	0
AURYXIA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
AUSTEDO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
AUVELITY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
AUVI-Q	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AVONEX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AVONEX PEN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AYVAKIT	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
AZASITE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AZATHIOPRINE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AZELAIC ACID	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
AZELASTINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AZELASTINE-FLUTICASONE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
AZELEX	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
AZOPT	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
AZSTARYS	0	0.0%	6	100.0%	0	0.0%	0	0.0%	6	0	0	0
BASAGLAR KWIKPEN U-100	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
BELBUCA	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
BELSOMRA	7	63.6%	4	36.4%	0	0.0%	0	0.0%	11	0	0	0
BENAZEPRIL HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BENLYSTA	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
BENZTROPINE MESYLATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BESIVANCE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BETAMETHASONE DIPROPIONATE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
BETAMETHASONE VALERATE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
BETOPTIC S	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BIKTARVY	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BIMATOPROST	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
BISOPROLOL FUMARATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BONJESTA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
BRAFTOVI	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BREO ELLIPTA	7	63.6%	4	36.4%	0	0.0%	0	0.0%	11	0	0	0
BREZTRI AEROSPHERE	1	20.0%	4	80.0%	0	0.0%	0	0.0%	5	0	0	0
BRIMONIDINE TARTRATE-TIMOLOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
BRINZOLAMIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
BRIVIACT	9	69.2%	4	30.8%	0	0.0%	0	0.0%	13	0	0	0
BUDESONIDE	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
BUDESONIDE ER	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
BUPRENORPHINE	27	81.8%	6	18.2%	0	0.0%	0	0.0%	33	0	0	0
BUPRENORPHINE HCL	10	90.9%	1	9.1%	0	0.0%	0	0.0%	11	0	0	0
BUPRENORPHINE-NALOXONE	16	88.9%	2	11.1%	0	0.0%	0	0.0%	18	0	0	0
BUPROPION HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
BUPROPION HCL SR	10	90.9%	1	9.1%	0	0.0%	0	0.0%	11	0	0	0
BUPROPION XL	10	83.3%	2	16.7%	0	0.0%	0	0.0%	12	0	0	0
BUSPIRONE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
BUTALB-ACETAMINOPH-CAFF-CODEIN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
BUTALBITAL-ACETAMINOPHEN-CAFFE	9	64.3%	5	35.7%	0	0.0%	0	0.0%	14	0	0	0
BYDUREON BCISE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
BYSTOLIC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CABOMETYX	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
CALCIPOTRIENE	9	64.3%	5	35.7%	0	0.0%	0	0.0%	14	0	0	0
CALCIPOTRIENE-CLOBETASOL PROP	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CALCITRIOL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CALQUENCE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CAMBIA	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
CANDESARTAN CILEXETIL	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
CANDESARTAN-HYDROCHLOROTHIAZID	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CAPLYTA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
CARBAMAZEPINE ER	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CARBATROL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CARBIDOPA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
CARBIDOPA-LEVODOPA	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
CARBIDOPA-LEVODOPA-ENTACAPONE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CARDIZEM CD	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CARTEOLOL HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CARVEDILOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CARVEDILOL ER	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CAYA CONTOURED	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CEFADROXIL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CEFPODOXIME PROXETIL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CELECOXIB	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CEQUA	2	33.3%	4	66.7%	0	0.0%	0	0.0%	6	0	0	0
CETROTIDE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CEVIMELINE HCL	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
CHLORZOXAZONE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CHOLESTYRAMINE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CICLODAN	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CICLOPIROX	3	30.0%	7	70.0%	0	0.0%	0	0.0%	10	0	0	0
CIMZIA	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
CIPRO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CITALOPRAM HBR	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
CLIMARA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CLINDAMYCIN HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CLINDAMYCIN PHOS-BENZOYL PEROX	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
CLINDAMYCIN PHOSPHATE	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
CLINDAMYCIN-BENZOYL PEROXIDE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CLOBAZAM	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CLOBETASOL PROPIONATE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
CLOMIPHENE CITRATE	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
CLONIDINE	7	87.5%	1	12.5%	0	0.0%	0	0.0%	8	0	0	0
CLONIDINE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CLONIDINE HCL ER	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
CLORAZEPATE DIPOASSIUM	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
COLCHICINE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
COMBIGAN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
COMBIPATCH	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
COMBIVENT RESPIMAT	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
CONCERTA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
CONTOUR NEXT TEST STRIP	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CONTRAVE	3	42.9%	4	57.1%	0	0.0%	0	0.0%	7	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
COPAXONE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
COPIKTRA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
CORLANOR	8	66.7%	4	33.3%	0	0.0%	0	0.0%	12	0	0	0
CORTIFOAM	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CORTROPHIN	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
COSENTYX PEN (2 PENS)	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
CRESEMBA	20	100.0%	0	0.0%	0	0.0%	0	0.0%	20	0	0	0
CROMOLYN SODIUM	6	66.7%	3	33.3%	0	0.0%	0	0.0%	9	0	0	0
CRYSSELLE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
CYANOCOBALAMIN INJECTION	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CYCLOBENZAPRINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CYCLOPENTOLATE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CYCLOSPORINE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
CYCLOSPORINE MODIFIED	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
CYTOMEL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
DABIGATRAN ETEXILATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DALIRESP	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
DAPSONE	7	41.2%	10	58.8%	0	0.0%	0	0.0%	17	0	0	0
DARIFENACIN ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DAYVIGO	15	75.0%	5	25.0%	0	0.0%	0	0.0%	20	0	0	0
DEPAKOTE	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
DEPAKOTE ER	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
DEPO-PROVERA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
DESCOVY	35	87.5%	5	12.5%	0	0.0%	0	0.0%	40	0	0	0
DESOXIMETASONE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
DESVENLAFAXINE ER	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
DESVENLAFAXINE SUCCINATE ER	48	81.4%	11	18.6%	0	0.0%	0	0.0%	59	0	0	0
DETROL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
DETROL LA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DEXAMETHASONE	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
DEXILANT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
DEXLANSOPRAZOLE DR	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
DEXMETHYLPHENIDATE HCL	6	66.7%	3	33.3%	0	0.0%	0	0.0%	9	0	0	0
DEXMETHYLPHENIDATE HCL ER	34	89.5%	4	10.5%	0	0.0%	0	0.0%	38	0	0	0
DEXTROAMPHETAMINE SULFATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DEXTROAMPHETAMINE-AMPHET ER	13	81.2%	3	18.8%	0	0.0%	0	0.0%	16	0	0	0
DEXTROAMPHETAMINE-AMPHETAMINE	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
DIAZEPAM	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
DIAZOXIDE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
DICLEGIS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DICLOFENAC POTASSIUM	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
DICLOFENAC SODIUM	2	40.0%	3	60.0%	0	0.0%	0	0.0%	5	0	0	0
DIFICID	22	71.0%	9	29.0%	0	0.0%	0	0.0%	31	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
DIFLUPREDNATE	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
DIHYDROERGOTAMINE MESYLATE	25	71.4%	10	28.6%	0	0.0%	0	0.0%	35	0	0	0
DILANTIN	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
DILTIAZEM 24HR ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DIMETHYL FUMARATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DIURIL	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
DIVIGEL	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
DOPTELET	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
DOTTI	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
DOXEPIN HCL	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
DOXYCYCLINE HYCLATE	2	40.0%	3	60.0%	0	0.0%	0	0.0%	5	0	0	0
DOXYCYCLINE IR-DR	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
DOXYLAMINE SUCC-PYRIDOXINE HCL	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
DROSPIRENONE-ETH ESTRA-LEVOMEF	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DROXIDOPA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DUEXIS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
DULERA	15	75.0%	5	25.0%	0	0.0%	0	0.0%	20	0	0	0
DULOXETINE HCL	6	85.7%	1	14.3%	0	0.0%	0	0.0%	7	0	0	0
DUPIXENT PEN	132	79.0%	35	21.0%	0	0.0%	0	0.0%	167	0	0	0
DUPIXENT SYRINGE	58	82.9%	12	17.1%	0	0.0%	0	0.0%	70	0	0	0
DUREZOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
DUTASTERIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
DYANAVEL XR	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ECEOXIA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ECONAZOLE NITRATE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
EFFER-K	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
ELIDEL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ELIQUIS	211	90.2%	23	9.8%	0	0.0%	0	0.0%	234	0	0	0
EMFLAZA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
EMGALITY PEN	74	78.7%	20	21.3%	0	0.0%	0	0.0%	94	0	0	0
EMGALITY SYRINGE	9	52.9%	8	47.1%	0	0.0%	0	0.0%	17	0	0	0
ENALAPRIL MALEATE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ENBREL	16	100.0%	0	0.0%	0	0.0%	0	0.0%	16	0	0	0
ENBREL SURECLICK	37	92.5%	3	7.5%	0	0.0%	0	0.0%	40	0	0	0
ENDOMETRIN	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
ENSTILAR	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ENVARUSUS XR	10	83.3%	2	16.7%	0	0.0%	0	0.0%	12	0	0	0
EPCLUSA	35	100.0%	0	0.0%	0	0.0%	0	0.0%	35	0	0	0
EPIDIOLEX	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
EPINEPHRINE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
EPIPEN 2-PAK	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
EPLERENONE	13	92.9%	1	7.1%	0	0.0%	0	0.0%	14	0	0	0
ERLEADA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ESBRIET	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ESCITALOPRAM OXALATE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ESOMEPRAZOLE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
MAGNESIUM												
ESTRADIOL	99	94.3%	6	5.7%	0	0.0%	0	0.0%	105	0	0	0
ESTRADIOL (TWICE WEEKLY)	39	88.6%	5	11.4%	0	0.0%	0	0.0%	44	0	0	0
ESTRADIOL VALERATE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ESTRADIOL-NORETHINDRONE ACETAT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ESTRING	17	70.8%	7	29.2%	0	0.0%	0	0.0%	24	0	0	0
ESTROGEL	3	42.9%	4	57.1%	0	0.0%	0	0.0%	7	0	0	0
ESZOPICLONE	18	81.8%	4	18.2%	0	0.0%	0	0.0%	22	0	0	0
ETHACRYNIC ACID	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ETHOSUXIMIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
EUCRISA	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
EVEROLIMUS	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
EVRYSDI	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
EXKIVITY	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
EYSUVIS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
FANAPT	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FARXIGA	13	48.1%	14	51.9%	0	0.0%	0	0.0%	27	0	0	0
FASENRA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FASENRA PEN	34	82.9%	7	17.1%	0	0.0%	0	0.0%	41	0	0	0
FEBUXOSTAT	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
FENTANYL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FER-IN-SOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FESOTERODINE	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
FUMARATE ER												
FETZIMA	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
FIASP	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
FINGOLIMOD	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
FIORICET	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FIORICET WITH CODEINE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
FLONASE ALLERGY RELIEF	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
FLOVENT HFA	18	60.0%	12	40.0%	0	0.0%	0	0.0%	30	0	0	0
FLUOCINOLONE ACETONIDE OIL	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
FLUOXETINE HCL	10	83.3%	2	16.7%	0	0.0%	0	0.0%	12	0	0	0
FLUTICASONE PROPRIONATE	0	0.0%	4	100.0%	0	0.0%	0	0.0%	4	0	0	0
FLUTICASONE PROPRIONATE HFA	6	46.2%	7	53.8%	0	0.0%	0	0.0%	13	0	0	0
FLUTICASONE-VILANTEROL	2	40.0%	3	60.0%	0	0.0%	0	0.0%	5	0	0	0
FLUVOXAMINE MALEATE ER	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
FOCALIN XR	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
FOLIC ACID	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
FONDAPARINUX SODIUM	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
FORTEO	42	84.0%	8	16.0%	0	0.0%	0	0.0%	50	0	0	0
FOSRENOL	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
FROVATRIPTAN SUCCINATE	3	33.3%	6	66.7%	0	0.0%	0	0.0%	9	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
FULPHILA	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
FUROSEMIDE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
FYCOMPA	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
GABAPENTIN	20	95.2%	1	4.8%	0	0.0%	0	0.0%	21	0	0	0
GALZIN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
GANIRELIX ACETATE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
GATTEX	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
GEMMILY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
GEMTESA	0	0.0%	11	100.0%	0	0.0%	0	0.0%	11	0	0	0
GEODON	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
GILENYA	21	95.5%	1	4.5%	0	0.0%	0	0.0%	22	0	0	0
GILOTRIF	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
GLIMEPIRIDE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
GLIPIZIDE	13	100.0%	0	0.0%	0	0.0%	0	0.0%	13	0	0	0
GLIPIZIDE ER	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
GLYCOPYRROLATE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
GOCOVRI	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
GRALISE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
GRANISETRON HCL	14	100.0%	0	0.0%	0	0.0%	0	0.0%	14	0	0	0
GRANIX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
GRASTEK	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
GVOKE HYOPEN 2-PACK	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
HAEGARDA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HAILEY 24 FE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
HEMANGEOL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
HORIZANT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
HUMALOG	25	100.0%	0	0.0%	0	0.0%	0	0.0%	25	0	0	0
HUMALOG JUNIOR KWIKPEN	76	100.0%	0	0.0%	0	0.0%	0	0.0%	76	0	0	0
HUMALOG KWIKPEN U-100	243	96.8%	8	3.2%	0	0.0%	0	0.0%	251	0	0	0
HUMALOG KWIKPEN U-200	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
HUMIRA	23	100.0%	0	0.0%	0	0.0%	0	0.0%	23	0	0	0
HUMIRA PEN	90	91.8%	8	8.2%	0	0.0%	0	0.0%	98	0	0	0
HUMIRA PEN CROHN'S-UC-HS	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
HUMIRA PEN PSOR-UVEITS-ADOL HS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
HUMIRA(CF)	15	88.2%	2	11.8%	0	0.0%	0	0.0%	17	0	0	0
HUMIRA(CF) PEDIATRIC CROHN'S	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
HUMIRA(CF) PEN	46	92.0%	4	8.0%	0	0.0%	0	0.0%	50	0	0	0
HUMIRA(CF) PEN CROHN'S-UC-HS	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
HUMIRA(CF) PEN PEDIATRIC UC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HUMULIN 70/30 KWIKPEN	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
HUMULIN N	16	100.0%	0	0.0%	0	0.0%	0	0.0%	16	0	0	0
HUMULIN N KWIKPEN	85	84.2%	16	15.8%	0	0.0%	0	0.0%	101	0	0	0
HUMULIN R	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
HUMULIN R U-500	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
HUMULIN R U-500 KWIKPEN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HYDRALAZINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HYDROCHLOROTHIAZIDE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
HYDROCODONE-ACETAMINOPHEN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
HYDROCODONE-IBUPROFEN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
HYDROCORTISONE-PRAMOXINE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
HYDROXYCHLOROQUINE SULFATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
HYDROXYZINE PAMOATE	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
HYOSCYAMINE SULFATE	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
HYOSCYAMINE SULFATE ER	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
HYPER-SAL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
IBUPROFEN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ICLUSIG	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
ICOSAPENT ETHYL	3	50.0%	3	50.0%	0	0.0%	0	0.0%	6	0	0	0
ILARIS	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ILEVRO	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
IMBRUVICA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
IMVEXXY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
INBRIJA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
INDAPAMIDE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
INDERAL LA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
INGREZZA	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
INLYTA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INPEN (FOR HUMALOG)	14	100.0%	0	0.0%	0	0.0%	0	0.0%	14	0	0	0
INPEN (FOR NOVOLOG OR FIASP)	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INREBIC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INSULIN ASPART	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
INSULIN ASPART FLEXPEN	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
INSULIN ASPART PENFILL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
INSULIN ASPART PROT MIX 70-30	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INSULIN DEGLUDEC	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
INSULIN DEGLUDEC PEN (U-100)	13	86.7%	2	13.3%	0	0.0%	0	0.0%	15	0	0	0
INSULIN GLARGINE	12	92.3%	1	7.7%	0	0.0%	0	0.0%	13	0	0	0
INSULIN GLARGINE SOLOSTAR	24	85.7%	4	14.3%	0	0.0%	0	0.0%	28	0	0	0
INSULIN GLARGINE-YFGN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INSULIN LISPRO JUNIOR KWIKPEN	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
INSULIN LISPRO KWIKPEN U-100	15	93.8%	1	6.2%	0	0.0%	0	0.0%	16	0	0	0
INSULIN SYRINGE	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
INSULIN SYRINGE U-500	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
INVOKANA	16	76.2%	5	23.8%	0	0.0%	0	0.0%	21	0	0	0
IPRATROPIUM BROMIDE	47	85.5%	8	14.5%	0	0.0%	0	0.0%	55	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
IPRATROPIUM-ALBUTEROL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
IRBESARTAN	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ITRACONAZOLE	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
IVERMECTIN	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
JAKAFI	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
JANUVIA	5	33.3%	10	66.7%	0	0.0%	0	0.0%	15	0	0	0
JARDIANCE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
JATENZO	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
JAVYGTOR	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
JOLESSA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
JORNAY PM	1	16.7%	5	83.3%	0	0.0%	0	0.0%	6	0	0	0
JUBLIA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
JYNARQUE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
KAPVAY	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
KEPPRA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
KEPPRA XR	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
KERENDIA	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
KESIMPTA PEN	5	50.0%	5	50.0%	0	0.0%	0	0.0%	10	0	0	0
KETAMINE HYDROCHLORIDE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
KETOCONAZOLE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
KETOROLAC TROMETHAMINE	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
KEVZARA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
KISQALI	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
LABETALOL HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LACOSAMIDE	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0
LACTULOSE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LAMICTAL	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
LAMOTRIGINE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
LAMOTRIGINE ODT	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LANTHANUM CARBONATE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
LANTUS	246	95.0%	13	5.0%	0	0.0%	0	0.0%	259	0	0	0
LANTUS SOLOSTAR	360	93.8%	24	6.2%	0	0.0%	0	0.0%	384	0	0	0
LASIX	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LATUDA	56	73.7%	20	26.3%	0	0.0%	0	0.0%	76	0	0	0
LAYOLIS FE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LENALIDOMIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LENVIMA	11	100.0%	0	0.0%	0	0.0%	0	0.0%	11	0	0	0
LEUCOVORIN CALCIUM	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LEUKINE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LEUPROLIDE ACETATE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
LEVEMIR	4	66.7%	2	33.3%	0	0.0%	0	0.0%	6	0	0	0
LEVEMIR FLEXTOUCH	10	71.4%	4	28.6%	0	0.0%	0	0.0%	14	0	0	0
LEVETIRACETAM	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
LEVONORG-ETH ESTRAD ETH ESTRAD	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LEVOTHYROXINE	4	44.4%	5	55.6%	0	0.0%	0	0.0%	9	0	0	0
LEVOTHYROXINE SODIUM	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
LEVOXYL	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
LEXAPRO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LIDOCAINE	1	20.0%	4	80.0%	0	0.0%	0	0.0%	5	0	0	0
LIDOCAINE HCL	2	33.3%	4	66.7%	0	0.0%	0	0.0%	6	0	0	0
LINZESS	46	48.4%	49	51.6%	0	0.0%	0	0.0%	95	0	0	0
LISINOPRIL	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
LISINOPRIL-HYDROCHLOROTHIAZIDE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
LITHIUM CARBONATE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
LIVALO	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
LIVTENCITY	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LO LOESTRIN FE	15	65.2%	8	34.8%	0	0.0%	0	0.0%	23	0	0	0
LOKELMA	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
LOPERAMIDE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LORBRENA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
LOSARTAN POTASSIUM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
LOSARTAN-HYDROCHLOROTHIAZIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
LOTEPREDNOL ETABONATE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
LUBIPROSTONE	226	97.0%	7	3.0%	0	0.0%	0	0.0%	233	0	0	0
LUCEMYRA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
LUMIGAN	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
LUNESTA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
LUPRON DEPOT	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
LYNPARZA	13	100.0%	0	0.0%	0	0.0%	0	0.0%	13	0	0	0
LYRICA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
LYUMJEV	14	73.7%	5	26.3%	0	0.0%	0	0.0%	19	0	0	0
LYUMJEV KWIKPEN U-100	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
MAVENCLAD	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MEDROXYPROGESTERONE ACETATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MEFENAMIC ACID	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MEKINIST	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
MEKTOVI	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MEMANTINE HCL ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MESALAMINE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
MESALAMINE ER	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
METFORMIN HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
METFORMIN HCL ER	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
METHOTREXATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
METHYLPHENIDATE ER	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
METHYLPHENIDATE ER (LA)	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
METHYLPHENIDATE HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
METHYLPHENIDATE HCL ER (CD)	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
METHYLPHENIDATE LA	2	33.3%	4	66.7%	0	0.0%	0	0.0%	6	0	0	0
METOPROLOL SUCCINATE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
METOPROLOL TARTRATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
MICARDIS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MICROGESTIN FE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MICROLET	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MIGRANAL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
MINOCYCLINE ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MIRTAZAPINE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
MODAFINIL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
MONTELUKAST SODIUM	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MORPHINE SULFATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MOTEGRITY	13	52.0%	12	48.0%	0	0.0%	0	0.0%	25	0	0	0
MOUNJARO	0	0.0%	64	100.0%	0	0.0%	0	0.0%	64	0	0	0
MOVANTIK	5	62.5%	3	37.5%	0	0.0%	0	0.0%	8	0	0	0
MOXIFLOXACIN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MULTAQ	8	88.9%	1	11.1%	0	0.0%	0	0.0%	9	0	0	0
MYCAPSSA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MYCOBUTIN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MYCOPHENOLATE MOFETIL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MYCOPHENOLIC ACID	20	100.0%	0	0.0%	0	0.0%	0	0.0%	20	0	0	0
MYDAYIS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MYFEMBREE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
MYFORTIC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
MYRBETRIQ	6	35.3%	11	64.7%	0	0.0%	0	0.0%	17	0	0	0
NAFTIFINE HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
NALOXONE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NANO 2ND GEN PEN NEEDLE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NAPROXEN	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
NATACYN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NATAZIA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NAYZILAM	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
NEBUSAL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NERLYNX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NEUPOGEN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NEUPRO	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
NEXAVAR	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
NEXIUM	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NEXLETOL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NEXLIZET	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NIFEDIPINE ER	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
NITAZOXANIDE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
NORA-BE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NOURIANZ	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NOVOLIN R FLEXPEN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
NOVOLOG	12	80.0%	3	20.0%	0	0.0%	0	0.0%	15	0	0	0
NOVOLOG FLEXPEN	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0
NOVOLOG MIX 70-30	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NOVOLOG PENFILL	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
NOVOPEN ECHO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NOXAFIL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NP THYROID	2	16.7%	10	83.3%	0	0.0%	0	0.0%	12	0	0	0
NUCALA	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
NUCYNTA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NUCYNTA ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
NUEDEXTA	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
NURTEC ODT	53	39.0%	83	61.0%	0	0.0%	0	0.0%	136	0	0	0
NUVARING	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
NUZYRA	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
OCALIVA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
OFEV	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
OLANZAPINE ODT	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
OLMESARTAN MEDOXOMIL	2	40.0%	3	60.0%	0	0.0%	0	0.0%	5	0	0	0
OLOPATADINE HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
OLUMIANT	7	63.6%	4	36.4%	0	0.0%	0	0.0%	11	0	0	0
OMEGA-3 ACID ETHYL ESTERS	7	70.0%	3	30.0%	0	0.0%	0	0.0%	10	0	0	0
OMEPRAZOLE	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
OMNIPOD 5 G6 INTRO KIT (GEN 5)	141	99.3%	1	0.7%	0	0.0%	0	0.0%	142	0	0	0
OMNIPOD 5 G6 PODS (GEN 5)	156	100.0%	0	0.0%	0	0.0%	0	0.0%	156	0	0	0
OMNIPOD CLASSIC PODS (GEN 3)	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
OMNIPOD DASH INTRO KIT (GEN 4)	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
OMNIPOD DASH PDM KIT (GEN 4)	18	94.7%	1	5.3%	0	0.0%	0	0.0%	19	0	0	0
OMNIPOD DASH PODS (GEN 4)	60	98.4%	1	1.6%	0	0.0%	0	0.0%	61	0	0	0
OMNITROPE	138	95.2%	7	4.8%	0	0.0%	0	0.0%	145	0	0	0
ONDANSETRON HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ONETOUCH DELICA	67	100.0%	0	0.0%	0	0.0%	0	0.0%	67	0	0	0
ONETOUCH DELICA PLUS LANCET	99	100.0%	0	0.0%	0	0.0%	0	0.0%	99	0	0	0
ONETOUCH LANCETS	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ONETOUCH ULTRA TEST STRIP	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
ONETOUCH VERIO TEST STRIP	187	99.5%	1	0.5%	0	0.0%	0	0.0%	188	0	0	0
ONFI	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ONGLYZA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
OPSUMIT	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
OPZELURA	3	37.5%	5	62.5%	0	0.0%	0	0.0%	8	0	0	0
ORENCIA	10	90.9%	1	9.1%	0	0.0%	0	0.0%	11	0	0	0
ORENCIA CLICKJECT	16	100.0%	0	0.0%	0	0.0%	0	0.0%	16	0	0	0
ORENITRAM ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ORLISSA	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
ORKAMBI	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ORLISTAT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ORPHENADRINE CITRATE ER	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
OVIDREL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
OXCARBAZEPINE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
OXISTAT	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
OXTELLAR XR	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
OXYCODONE HCL	9	81.8%	2	18.2%	0	0.0%	0	0.0%	11	0	0	0
OXYCODONE HCL ER	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
OXYCODONE-ACETAMINOPHEN	0	0.0%	4	100.0%	0	0.0%	0	0.0%	4	0	0	0
OXYCONTIN	11	57.9%	8	42.1%	0	0.0%	0	0.0%	19	0	0	0
OZEMPIC	155	53.8%	133	46.2%	0	0.0%	0	0.0%	288	0	0	0
PALIPERIDONE ER	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
PALYNZIQ	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
PANTOPRAZOLE SODIUM	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
PAROXETINE ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PAROXETINE MESYLATE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
PEMAZYRE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PEN NEEDLE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PERFOROMIST	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PERPHENAZINE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PHENTERMINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PIMECROLIMUS	11	64.7%	6	35.3%	0	0.0%	0	0.0%	17	0	0	0
PIQRAY	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
PIRFENIDONE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
POLYMYXIN B SUL-TRIMETHOPRIM	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
POMALYST	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
PORTIA	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
POSACONAZOLE	18	85.7%	3	14.3%	0	0.0%	0	0.0%	21	0	0	0
POTASSIUM CHLORIDE	6	75.0%	2	25.0%	0	0.0%	0	0.0%	8	0	0	0
PRADAXA	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
PRALUENT PEN	4	66.7%	2	33.3%	0	0.0%	0	0.0%	6	0	0	0
PRAMIPEXOLE ER	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
PRECISION XTRA	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
PREDNISOLONE ACETATE	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
PREMARIN	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
PREMPRO	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
PREVYMIS	14	100.0%	0	0.0%	0	0.0%	0	0.0%	14	0	0	0
PRIFTIN	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PRIMIDONE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PROAIR HFA	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
PROCTOFOAM-HC	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
PROGESTERONE	36	56.2%	28	43.8%	0	0.0%	0	0.0%	64	0	0	0
PROGRAF	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
PROLENSA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PROMACTA	10	90.9%	1	9.1%	0	0.0%	0	0.0%	11	0	0	0
PROPAFENONE HCL ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PROPRANOLOL HCL ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
PROVENTIL HFA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
PULMICORT FLEXHALER	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
QBREXZA	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
QELBREE	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
QINLOCK	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
QNASL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
QSYMIA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
QUETIAPINE FUMARATE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
QUETIAPINE FUMARATE ER	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
QUILLICHEW ER	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
QUILLIVANT XR	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
QUINAPRIL HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
QULIPTA	6	37.5%	10	62.5%	0	0.0%	0	0.0%	16	0	0	0
QUVIVIQ	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
QVAR REDHALER	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
RABEPRAZOLE SODIUM	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
RAMELTEON	24	92.3%	2	7.7%	0	0.0%	0	0.0%	26	0	0	0
RAMIPRIL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
RANEXA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
RANOLAZINE ER	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
RASAGILINE MESYLATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
RASUVO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
REBIF	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
REBIF REBIDOSE	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
RELISTOR	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
REPAGLINIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
REPATHA SURECLICK	105	89.0%	13	11.0%	0	0.0%	0	0.0%	118	0	0	0
REPATHA SYRINGE	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
RESTASIS	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0
RESTASIS MULTIDOSE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
RETEVMO	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
RETIN-A	575	98.6%	8	1.4%	0	0.0%	0	0.0%	583	0	0	0
REVLIMID	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
REXULTI	7	70.0%	3	30.0%	0	0.0%	0	0.0%	10	0	0	0
REYVOW	2	28.6%	5	71.4%	0	0.0%	0	0.0%	7	0	0	0
REZUROCK	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
RHOFADE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
RHOPRESSA	26	89.7%	3	10.3%	0	0.0%	0	0.0%	29	0	0	0
RIFABUTIN	6	100.0%	0	0.0%	0	0.0%	0	0.0%	6	0	0	0
RINVOQ	16	72.7%	6	27.3%	0	0.0%	0	0.0%	22	0	0	0
RISEDRONATE SODIUM	15	93.8%	1	6.2%	0	0.0%	0	0.0%	16	0	0	0
RISPERIDONE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
RITALIN	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
RIVASTIGMINE	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
ROCKLATAN	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
RUFINAMIDE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
RYBELSUS	2	14.3%	12	85.7%	0	0.0%	0	0.0%	14	0	0	0
RYDAPT	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
RYTARY	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
SAIZEN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SAPHRIS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
SAVELLA	9	90.0%	1	10.0%	0	0.0%	0	0.0%	10	0	0	0
SAXENDA	1	11.1%	8	88.9%	0	0.0%	0	0.0%	9	0	0	0
SERTRALINE HCL	12	66.7%	6	33.3%	0	0.0%	0	0.0%	18	0	0	0
SEVELAMER CARBONATE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
SILDENAFIL CITRATE	8	80.0%	2	20.0%	0	0.0%	0	0.0%	10	0	0	0
SILODOSIN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SIMBRINZA	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
SIMPONI	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
SIROLIMUS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
SIVEXTRO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
SKYRIZI	7	63.6%	4	36.4%	0	0.0%	0	0.0%	11	0	0	0
SKYRIZI ON-BODY	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SKYRIZI PEN	9	56.2%	7	43.8%	0	0.0%	0	0.0%	16	0	0	0
SKYTROFA	0	0.0%	7	100.0%	0	0.0%	0	0.0%	7	0	0	0
SLYND	7	46.7%	8	53.3%	0	0.0%	0	0.0%	15	0	0	0
SODIUM CHLORIDE	18	100.0%	0	0.0%	0	0.0%	0	0.0%	18	0	0	0
SOFOBUVIR-VELPATASVIR	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
SOMAVERT	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
SORAFENIB	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
SPINOSAD	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
SPIRIVA HANDIHALER	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
SPIRIVA RESPIMAT	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
SPIRONOLACTONE	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
SPRINTEC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
SPRYCEL	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
STELARA	69	92.0%	6	8.0%	0	0.0%	0	0.0%	75	0	0	0
STIVARGA	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
STRENSIQ	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
STRIBILD	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
SUCRAID	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
SUCRALFATE	17	68.0%	8	32.0%	0	0.0%	0	0.0%	25	0	0	0
SUMATRIPTAN SUCCINATE	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
SUNOSI	19	90.5%	2	9.5%	0	0.0%	0	0.0%	21	0	0	0
SUTAB	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
SYMBICORT	7	100.0%	0	0.0%	0	0.0%	0	0.0%	7	0	0	0
SYMDEKO	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SYMPROIC	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SYMTUZA	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
SYNJARDY	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
SYNJARDY XR	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
SYNTHROID	6	18.2%	27	81.8%	0	0.0%	0	0.0%	33	0	0	0
TABRECTA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TACROLIMUS	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
TADALAFIL	5	50.0%	5	50.0%	0	0.0%	0	0.0%	10	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
TAFINLAR	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
TAGRISSO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TAKHZYRO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TALTZ AUTOINJECTOR	5	38.5%	8	61.5%	0	0.0%	0	0.0%	13	0	0	0
TALTZ AUTOINJECTOR (3 PACK)	0	0.0%	4	100.0%	0	0.0%	0	0.0%	4	0	0	0
TALTZ SYRINGE	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
TAMSULOSIN HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TASIGNA	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
TAVALISSE	3	75.0%	1	25.0%	0	0.0%	0	0.0%	4	0	0	0
TEGRETOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TELMISARTAN	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
TELMISARTAN-HYDROCHLOROTHIAZID	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TEMAZEPAM	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TERCONAZOLE	5	100.0%	0	0.0%	0	0.0%	0	0.0%	5	0	0	0
TESTOSTERONE	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
TESTOSTERONE CYPIONATE	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TESTOSTERONE ENANTHATE	3	42.9%	4	57.1%	0	0.0%	0	0.0%	7	0	0	0
TETRACAINE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TEZSPIRE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
THIOLA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
THIOLA EC	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
TIBSOVO	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TIMOLOL MALEATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TINIDAZOLE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TIROSINT	2	25.0%	6	75.0%	0	0.0%	0	0.0%	8	0	0	0
TIROSINT-SOL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TIZANIDINE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TLANDO	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TOBRADEX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TOBRAMYCIN-DEXAMETHASONE	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TOLTERODINE TARTRATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TOLTERODINE TARTRATE ER	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
TOPAMAX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TOPIRAMATE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TORSEMIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TOSYMRA	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TOUJEO MAX SOLOSTAR	2	22.2%	7	77.8%	0	0.0%	0	0.0%	9	0	0	0
TOUJEO SOLOSTAR	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
TRADJENTA	12	54.5%	10	45.5%	0	0.0%	0	0.0%	22	0	0	0
TRAMADOL HCL ER	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
TRANEXAMIC ACID	18	52.9%	16	47.1%	0	0.0%	0	0.0%	34	0	0	0
TRANSDERM-SCOP	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TRAVOPROST	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TRAZODONE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
TRELEGY ELLIPTA	4	14.8%	23	85.2%	0	0.0%	0	0.0%	27	0	0	0
TREMFYA	16	76.2%	5	23.8%	0	0.0%	0	0.0%	21	0	0	0
TRESIBA	5	71.4%	2	28.6%	0	0.0%	0	0.0%	7	0	0	0
TRESIBA FLEXTOUCH U-100	14	60.9%	9	39.1%	0	0.0%	0	0.0%	23	0	0	0
TRESIBA FLEXTOUCH U-200	5	55.6%	4	44.4%	0	0.0%	0	0.0%	9	0	0	0
TRETINOIN	11	78.6%	3	21.4%	0	0.0%	0	0.0%	14	0	0	0
TRIAMCINOLONE ACETONIDE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TRIENTINE HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TRIHEXYPHENIDYL HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TRIKAFTA	9	100.0%	0	0.0%	0	0.0%	0	0.0%	9	0	0	0
TRILEPTAL	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TRIMETHOBENZAMIDE HCL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TRIMO-SAN	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
TRINTELLIX	48	69.6%	21	30.4%	0	0.0%	0	0.0%	69	0	0	0
TRIUMEQ	25	92.6%	2	7.4%	0	0.0%	0	0.0%	27	0	0	0
TROKENDI XR	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
TROSPIUM CHLORIDE ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TRULANCE	102	95.3%	5	4.7%	0	0.0%	0	0.0%	107	0	0	0
TRULICITY	10	16.4%	51	83.6%	0	0.0%	0	0.0%	61	0	0	0
TUKYSA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
TYMLOS	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
TYRVAYA	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
UBRELVY	142	83.0%	29	17.0%	0	0.0%	0	0.0%	171	0	0	0
UCERIS	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ULTRA-FINE NANO PEN NEEDLE	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ULTRA-FINE SHORT PEN NEEDLE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
UNITHROID	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
UPTRAVI	8	100.0%	0	0.0%	0	0.0%	0	0.0%	8	0	0	0
UREA	0	0.0%	2	100.0%	0	0.0%	0	0.0%	2	0	0	0
URO-MP	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
UROGESIC-BLUE	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
V-GO 20	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
VAGIFEM	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
VALACYCLOVIR	18	52.9%	16	47.1%	0	0.0%	0	0.0%	34	0	0	0
VALCHLOR	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VALCYTE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VALSARTAN	1	33.3%	2	66.7%	0	0.0%	0	0.0%	3	0	0	0
VALSARTAN-HYDROCHLOROTHIAZIDE	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
VALTOCO	3	37.5%	5	62.5%	0	0.0%	0	0.0%	8	0	0	0
VARENICLINE TARTRATE	2	66.7%	1	33.3%	0	0.0%	0	0.0%	3	0	0	0
VASCEPA	4	80.0%	1	20.0%	0	0.0%	0	0.0%	5	0	0	0
VELPHORO	3	60.0%	2	40.0%	0	0.0%	0	0.0%	5	0	0	0
VELTASSA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VEMLIDY	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
VENCLEXTA	10	100.0%	0	0.0%	0	0.0%	0	0.0%	10	0	0	0
VENCLEXTA STARTING PACK	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
VENLAFAXINE HCL	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
VENLAFAXINE HCL ER	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VENTOLIN HFA	11	64.7%	6	35.3%	0	0.0%	0	0.0%	17	0	0	0
VEO INSULIN SYRINGE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VERAPAMIL HCL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VERZENIO	10	66.7%	5	33.3%	0	0.0%	0	0.0%	15	0	0	0
VIBERZI	4	57.1%	3	42.9%	0	0.0%	0	0.0%	7	0	0	0
VICTOZA 2-PAK	48	54.5%	40	45.5%	0	0.0%	0	0.0%	88	0	0	0
VICTOZA 3-PAK	7	63.6%	4	36.4%	0	0.0%	0	0.0%	11	0	0	0
VIIBRYD	19	95.0%	1	5.0%	0	0.0%	0	0.0%	20	0	0	0
VILAZODONE HCL	35	85.4%	6	14.6%	0	0.0%	0	0.0%	41	0	0	0
VIMPAT	14	66.7%	7	33.3%	0	0.0%	0	0.0%	21	0	0	0
VITAMIN D2	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VIVELLE-DOT	2	50.0%	2	50.0%	0	0.0%	0	0.0%	4	0	0	0
VOLTAREN ARTHRITIS PAIN	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
VONJO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VORICONAZOLE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VOXZOGO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
VRAYLAR	36	78.3%	10	21.7%	0	0.0%	0	0.0%	46	0	0	0
VUMERITY	1	20.0%	4	80.0%	0	0.0%	0	0.0%	5	0	0	0
VYNDAMAX	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
VYVANSE	230	70.3%	97	29.7%	0	0.0%	0	0.0%	327	0	0	0
VYZULTA	4	100.0%	0	0.0%	0	0.0%	0	0.0%	4	0	0	0
WAKIX	12	92.3%	1	7.7%	0	0.0%	0	0.0%	13	0	0	0
WARFARIN SODIUM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
WEGOVY	1	6.7%	14	93.3%	0	0.0%	0	0.0%	15	0	0	0
WELLBUTRIN SR	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
WELLBUTRIN XL	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
WIDE SEAL DIAPHRAGM	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
WINLEVI	2	22.2%	7	77.8%	0	0.0%	0	0.0%	9	0	0	0
WIXELA INHUB	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
XARELTO	161	93.6%	11	6.4%	0	0.0%	0	0.0%	172	0	0	0
XATMEP	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
XCOPRI	7	70.0%	3	30.0%	0	0.0%	0	0.0%	10	0	0	0
XELJANZ	6	60.0%	4	40.0%	0	0.0%	0	0.0%	10	0	0	0
XENICAL	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
XIFAXAN	56	40.9%	81	59.1%	0	0.0%	0	0.0%	137	0	0	0
XIIDRA	31	72.1%	12	27.9%	0	0.0%	0	0.0%	43	0	0	0
XIMINO	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
XOLAIR	17	85.0%	3	15.0%	0	0.0%	0	0.0%	20	0	0	0
XOSPATA	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
XTAMPZA ER	1	14.3%	6	85.7%	0	0.0%	0	0.0%	7	0	0	0
XYOSTED	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
XYREM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
XYWAV	13	72.2%	5	27.8%	0	0.0%	0	0.0%	18	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Drug Name

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Drug Name	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
YASMIN 28	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
YUVAFEM	15	75.0%	5	25.0%	0	0.0%	0	0.0%	20	0	0	0
ZAFIRLUKAST	1	50.0%	1	50.0%	0	0.0%	0	0.0%	2	0	0	0
ZALEPLON	5	83.3%	1	16.7%	0	0.0%	0	0.0%	6	0	0	0
ZEJULA	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ZELNORM	3	100.0%	0	0.0%	0	0.0%	0	0.0%	3	0	0	0
ZENPEP	2	100.0%	0	0.0%	0	0.0%	0	0.0%	2	0	0	0
ZEPOSIA	6	66.7%	3	33.3%	0	0.0%	0	0.0%	9	0	0	0
ZIOPTAN	4	66.7%	2	33.3%	0	0.0%	0	0.0%	6	0	0	0
ZIRGAN	1	25.0%	3	75.0%	0	0.0%	0	0.0%	4	0	0	0
ZOLMITRIPTAN	10	62.5%	6	37.5%	0	0.0%	0	0.0%	16	0	0	0
ZOLMITRIPTAN ODT	0	0.0%	3	100.0%	0	0.0%	0	0.0%	3	0	0	0
ZOLPIDEM TARTRATE ER	4	66.7%	2	33.3%	0	0.0%	0	0.0%	6	0	0	0
ZONISADE	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
ZORVOLEX	0	0.0%	1	100.0%	0	0.0%	0	0.0%	1	0	0	0
ZUBSOLV	1	100.0%	0	0.0%	0	0.0%	0	0.0%	1	0	0	0
Overall - Summary	8,040	78.9%	2,155	21.1%	0	0.0%	0	0.0%	10,195	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Preauthorization Rates by Denial Type

KAISER PERMANENTE

Last Process Status Date: 01/01/2022 through 12/31/2022

*Identification Independent Review Organization depends upon the appeal being processed through the MRA system. If the appeal is processed through a different source, all overturned appeals will be counted as internal.

Denial Type	Approved	Approved %	Denied	Denied %	Partial Approved	Partial Approved %	Other	Other %	Total PA Count	Denial Overturned - Internal Appeal	Denials Overturned - IRO	Total Overturned
ADMINISTRATIVE	0	0.0%	188	100.0%	0	0.0%	0	0.0%	188	0	0	0
CLINICAL NECESSITY	1	0.1%	966	99.9%	0	0.0%	0	0.0%	967	0	0	0
NA	8,039	88.9%	1,001	11.1%	0	0.0%	0	0.0%	9,040	0	0	0
Overall - Summary	8,040	78.9%	2,155	21.1%	0	0.0%	0	0.0%	10,195	0	0	0

Copyright © 2020-2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.